Overview

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

Status:
Completed

Trial end date:
2021-07-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of co-administration of ABT-493/ABT-530 plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 - 6-infected participants (including non-cirrhotic, or cirrhotic with compensated cirrhosis participants) who have experienced virologic failure in an AbbVie parent clinical study.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Ribavirin
Sofosbuvir